DeepNewz, mobile.

People-sourced. AI-powered. Unbiased News.

Screenshot of DeepNewz app showing story detail view.

Screenshot of DeepNewz app showing story list view.

Apellis News

FDA Approves Apellis’ EMPAVELI for Rare Kidney Diseases in Patients 12+, Showing 68% Proteinuria Reduction; Q2 Revenue $178M

Company Earnings

FDA Approves Apellis’ EMPAVELI for Rare Kidney Diseases in Patients 12+, Showing 68% Proteinuria Reduction; Q2 Revenue $178M

9

2 days ago

Latest stories